Prosidion, Aestus partner for pain compound

Prosidion Ltd., a subsidiary of Astellas Pharma Inc. (Tokyo:4503), granted Aestus Therapeutics Inc. (North Brunswick, N.J.) exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN) by the end of 2012. Terms were not disclosed. Astellas acquired PSN357 through its acquisition of OSI Pharmaceuticals Inc. last year. ...